作者
Mingtong Xu,Zhen Wang,Yumin Zhang,Lei Zhu,Rongjie Huang,Xuebin Han,Zhuhua Yao,Jiao Sun,Tian Feng-sheng,Xitian Hu,Liping Ma,Chunlin Lai,Xiwen Zhang,Jianlong Sheng,Qinghua Han,C Jin,Li Luo,Ruiping Zhao,Liwen Li,Biao Xu,Delu Yin,Suxin Luo,Xiaofeng Ge,Zhiyuan Liu,Ping Yang,Zheng Huang,Tianfa Li,Wei Ma,Yanqing Wu,Zhiyu Ling,Likun Ma,Chao Lv,Chanjuan Deng,Wenhua Wei,Ying Wang,Yan Li,Junbo Ge
摘要
Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have been used to reduce the level of low-density lipoprotein cholesterol (LDL-C), but require either biweekly or monthly dosing frequency. Recaticimab is a new humanized monoclonal antibody selectively targeting PCSK9, with long-acting characteristic.
Singularity
不配.
穆紫
坚强的广山
互助遵法尚德
paparazzi221
lch23560
带头大哥
Yziii
HEIKU
寻道图强
Leonardi
好困
zho
shinysparrow
pcr163
夏远航
InfoNinja
子车茗
pluto
皖公网安备34019202002308
